Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 10.32p 10.28p 10.36p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -7.0 -4.8 - 14.39

Immupharma Share Discussion Threads

Showing 34051 to 34075 of 34075 messages
Chat Pages: 1363  1362  1361  1360  1359  1358  1357  1356  1355  1354  1353  1352  Older
DateSubjectAuthorDiscuss
22/5/2019
12:36
Why would the directors, who own >20% of Immupharma, put it into administration? What a ridiculous suggestion. The reality is that if the current strategy is executed Immupharma would in effect be a holding company. A) It would own license revenues for P140 / Lupuzor B) It would own shares in the floated Urelix / Nucant subsidiary C) It would own shares in Incathera All those are potentially very valuable assets. A) and B) in particular.
sicilian_kan
22/5/2019
12:08
If they float off the rest of the pipeline into another company as planned, that just leaves IMM with Lupuzor which failed Phase 3, so presumably then IMM can be put into administration, and the management just transfer over to the new company to repeat the same old rinse and repeat share issue-dilution-failure process to unsuspecting French investors this time rather than trying to return to the London market.You couldn't make it up.
ken chung
21/5/2019
14:07
Is Kirk Tim McCarthy?......the ramping seems familiar
kop202
21/5/2019
10:18
just turned blue - big background buyer
reks
21/5/2019
09:09
Massive potential upside here
kirk 6
20/5/2019
17:14
start of the rerate? if results good it could blow the price away rise in anticipation i suppose
reks
20/5/2019
16:42
These you go 10.5
kirk 6
20/5/2019
16:18
A close above 10p would be a really strong signal.
sicilian_kan
20/5/2019
15:40
Looking like these are going to fly
kirk 6
17/5/2019
14:03
The results are useless they are just playing for time and taking those few investors left how still believe that there is still hope for there last pennies please don't be fooled
best1467
17/5/2019
09:35
borromini1 im sure you are correct,and to be thorough,data takes time to process, however the overriding immediate impact may be staring at them from the department of the bleeding obvious..who knows..ps i didnt suggest anywhere that they were doing anything secretly, that was you..
brad44
17/5/2019
09:05
Brad - are IMM not required by AIM rules to promptly announce to market price sensitive news, such as the OLE results? Your idea that they have received the results already and are secretly taking weeks or months discussing these results and their implications with selected others is surely untenable.
borromini1
16/5/2019
11:20
borromini1 there is still the outcome of the extended progamme to consider, maybe that brought up or highlighted something more in terms of the P140, which is being alluded to? in any event, we haven't got long to wait. I hope the outcome is a positive one for the shareholders and for those with illness. I remain invested here
brad44
16/5/2019
07:45
At the last AGM Dimitri and Robert stated that doing a deal with big pharma was a good answer and if such a deal was in the offing they would consider it, but in the mean time they had a better idea. That idea turned out to be the MAP. 11 months later Dimitri announces a pause in progressing the MAP with a slightly nebulous reason given, but given a context of previous scant detail given on the MAP, it’s timeline or key milestones, and equivocation in the language of the RNS we are left guessing as to if it’s a problem, maybe temporarily maybe permanent, with the MAP, therefore necessitating pursuing an inferior option, or rather a better option or options with big pharma or not so big pharma coming to the fore, except added to the current mix is an equally nebulous idea of timeline or certainty of one of these even coming to pass. Take your pick, hint of something dramatic about to happen or signalling another failing route to market, or able to sit on the side lines and wait to see what transpires? So far I’ve averaged down in a small way in the dip of the last two days.
borromini1
16/5/2019
07:08
Was in these up run up to results sold some pre the rest after in the 30p range I would strongly advise anyone thinking of investing to not to the company will be looking to raise cash in the next 12 months which if manage to which I doubt will wipe your holding out. Pre the Lupuzor result they struggled to raise cash to complete the p3 trail I’m afraid it’s worthless .
best1467
16/5/2019
01:16
12 red zero section
kirk 6
15/5/2019
22:42
borromini1, people already have paid 18-20p before the facts appeared. And for the same reason DavR0s, the 18-20p range is not an arbitrary made up price. The last two spikes, both in the past 6 months, hit 18.5p and 21.5p. We now know more than we did then. See the chart below: free stock charts from uk.advfn.com
sicilian_kan
15/5/2019
21:59
12 - another random number
davr0s
15/5/2019
21:56
Go for 30p mate
kirk 6
15/5/2019
21:23
I can see them hitting.... let me think.... any random number I might come up with. Hangon here it comes 854. There
davr0s
15/5/2019
21:03
Can see these hitting 30p shortly
kirk 6
15/5/2019
20:48
What's a target price? Some arbitrary price that someone you don't know has made up and have no idea what their motivation is. It's meaningless noise. Anyhow why are people still here trying to make money on this share - there must be better opportunities in the market surely?
davr0s
15/5/2019
19:57
Hi SK - it was a conceit, you are assuming some one or some thing is going to pay 18-20p before the facts appear. As for potential MAP problems, how about a regulatory requirement for positive results from the Open Label Extension? Does it not jar a little when the references are always to regulatory ADVISORS rather than the real thing or do you somehow fall for conflating the two?
borromini1
15/5/2019
19:08
Hi Borromini1. Why would I buy shares at a target price? That doesn’t make any sense at all. The whole point of investing is to buy cheaper than the target price. Had the MAP run into problems why would they postpone the MAP process pending (in part) ongoing engagement with potential corporate partners.
sicilian_kan
15/5/2019
18:53
SK - I thought November and February had punished those that bought the rumour. Why not wait until the facts turn up? Please point out the part that states the MAP had regulatory approval to proceed rather than running into a roadblock, thereby necessitating the strategy change. Why wait for your target price I can sell you some IMM shares for 18-20p here and now, how many do you want?
borromini1
Chat Pages: 1363  1362  1361  1360  1359  1358  1357  1356  1355  1354  1353  1352  Older
Your Recent History
LSE
IMM
Immupharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190524 05:55:18